Abeona Therapeutics Inc. (ABEO) Stock Rating Reaffirmed by Jefferies Group LLC

Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Group LLC in a research note issued to investors on Friday. They currently have a $11.00 price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective would indicate a potential upside of 83.33% from the stock’s previous close.

A number of other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, February 8th. HC Wainwright set a $20.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Monday, February 6th. Rodman & Renshaw reaffirmed a “buy” rating and set a $20.00 target price (up previously from $17.00) on shares of Abeona Therapeutics in a research note on Tuesday, February 7th. Maxim Group set a $14.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 18th. Finally, Cantor Fitzgerald set a $21.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 12th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $15.18.

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at 6.00 on Friday. The firm’s market cap is $239.75 million. The company’s 50-day moving average price is $5.21 and its 200 day moving average price is $5.51. Abeona Therapeutics has a 52 week low of $2.05 and a 52 week high of $9.44.

“Abeona Therapeutics Inc. (ABEO) Stock Rating Reaffirmed by Jefferies Group LLC” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another website, it was illegally copied and republished in violation of United States & international copyright legislation. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/02/21/abeona-therapeutics-inc-abeo-stock-rating-reaffirmed-by-jefferies-group-llc.html.

Several hedge funds have recently modified their holdings of ABEO. RTW Investments LLC acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at $116,000. Ardsley Advisory Partners acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at $120,000. A.R.T. Advisors LLC acquired a new stake in shares of Abeona Therapeutics during the fourth quarter valued at $117,000. Tudor Investment Corp Et Al acquired a new stake in shares of Abeona Therapeutics during the fourth quarter valued at $162,000. Finally, GLG Partners LP acquired a new stake in shares of Abeona Therapeutics during the fourth quarter valued at $186,000. 17.79% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

5 Day Chart for NASDAQ:ABEO

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply